AMGEN TO PRESENT NEW DATA ACROSS RARE AND OTHER SERIOUS AUTOIMMUNE DISEASES AT ACR CONVERGENCE 2026
Phase 3 OASIZ-301 Study of Dazodalibep in Sjögren's Disease Shows Statistically Significant and Clinically Meaningful Improvement in Systemic Disease Activity and Patient-Reported Dryness New Long-Term UPLIZNA Data in IgG4-Related Disease and Real-World Evidence for KRYSTEXXA and TAVNEOS...
Covered in this story
Analyst targets on Ultragenyx Pharmaceutical
- H.C. Wainwright: $25.6 → $50 by Aug 2027 · Buy via Investing.com
- Wells Fargo: $25.6 → $50 by Aug 2027 · Overweight via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $RARE yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Ultragenyx Pharmaceutical →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.